Chembio diagnostics submits fda de novo/510(k) request for dpp sars-cov-2 antigen test system

Hauppauge, n.y., dec. 06, 2021 (globe newswire) -- chembio diagnostics, inc. (nasdaq: cemi), a leading point-of-care diagnostics company focused on infectious diseases, today announced that it has submitted a de novo/510(k) request to the u.s. food and drug administration (fda) for the dpp sars-cov-2 antigen test system.
CEMI Ratings Summary
CEMI Quant Ranking